Search

Author/Creator Harbison, C.T.

1. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). (September 2015)

Authors:
Horn, L.; Brahmer, J.; Reck, M.; Borghaei, H.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.J.; Burgio, M.A.; Fayette, J.; Gettinger, S.N.; Harbison, C.T.; Li, A.; Finckenstein, F.G.; Paz-Ares, L.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S599
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. (September 2015)

Authors:
Gettinger, S.N.; Hellmann, M.D.; Shepherd, F.A.; Antonia, S.J.; Brahmer, J.; Chow, L.Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N.E.; Gerber, D.E.; Nathan, F.; Shen, Y.; Harbison, C.T.; Rizvi, N.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S632
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). (September 2015)

Authors:
Hellmann, M.D.; Rizvi, N.; Gettinger, S.N.; Goldman, J.; Chow, L.Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C.T.; Nathan, F.; Ready, N.E.; Antonia, S.J.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S632
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search